Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • uddi_uddi_javan uddi_uddi_javan Jun 6, 2011 8:26 PM Flag

    Deaths in study...not good

    Yes, FDA is always concerned on safety issues.

    See BMTI after after panel negative comments about saftey and see now where it is closed today. $14 - $6.64

    SAFETY A PRIME CONCERN FOR FDA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Of course the FDA focus's on safety, but relative to existing treatments and disease. Don't you think that all the Chemotherapies on the market today for late stage cancers have deaths? The answer is an absolute yes. Unfortunately. But the FDA will balance the safety concerns with the benefits in determining approval. The cabo data looks pretty remarkable. And the 1.2% mortality rate, while tragic, appears to be no worse than other treatments IMHO.

    • then explain how DNDN did it with death. Look where DNDN today. They are in the 30s.
      HOw old are you? are you like 15, you should never invest in bio stock without having an understanding of test trial is.

      No drug including DNDN is perfect. It is not god. it is a test drug which can heal and control cancer and extend life.

      Stop posting if you fail to understand, unless you are of them, golden sach hired bashers to keep the price down for strategically making EXEL most attractive for a easy buy-out. You hear that right. This is better than ever. Buy-out price for the most effective and unique cancer drug CABO out there at attractive price.

      Golden opportunity to load up some more. No guts no gain.

    • what is the rate of death in the placebo population for crpc?

    • just cover in the morning, you'll be alright.

 
EXEL
8.83+0.07(+0.80%)9:44 AMEDT